The adenosine neuromodulation system in schizophrenia.

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Schizophrenia management remains challenging, necessitating novel therapeutic strategies for positive, negative, and cognitive symptoms.
• The adenosine modulation system is increasingly recognized for its potential in treating schizophrenia core features.

Purpose of the Study:

• To review evidence supporting adenosine system modulation for schizophrenia endophenotypes.
• To propose a novel hypothesis on adenosine A1 and A2A receptor roles in schizophrenia pathogenesis.
• To guide the design of future therapeutic interventions targeting the adenosine system.

Main Methods:

• Review of existing scientific literature on adenosine modulation, dopaminergic signaling, working memory, and neurodevelopment in schizophrenia.
• Analysis of the roles of adenosine A1 and A2A receptors in neuronal circuits and information processing.
• Formulation of a working hypothesis based on the combined roles of adenosine levels and receptor function.

Main Results:

• Adenosine A2A receptor modulation impacts dopaminergic signaling, working memory, and behavioral sensitization.
• Therapies increasing extracellular adenosine (e.g., dipyridamole, allopurinol) show potential clinical effectiveness.
• Adenosine plays a role in neurodevelopment, and A1/A2A receptors are crucial for adaptive changes and information salience encoding.

Conclusions:

• An imbalance in adenosine formation and A1/A2A receptor function may impair information salience encoding, contributing to schizophrenia endophenotypes.
• Future therapies should simultaneously target adenosine kinase-A1 receptors and A2A receptors for effective schizophrenia management.
• Targeting the adenosine modulation system offers a promising avenue for developing novel schizophrenia treatments.